I think 30 million of the 80 million have been allocated already, but September will be an interesting month for ECQ, with the election, more EU bailout meetings, and if the Fed announces tapering, and the fact that traditionally it ranks as the highest declining stock price month on the ASX (on average).
Hopefully, the next month will see some stock price appreciation in order to have a buffer into September. I know a lot of people just aren't buying now, not until October at the earliest, plenty of professionals just watching what the international markets are going to do into the last quarter.
Anyway, the world now currently has it's first two patient offered stem cell treatments, and globally, it looks like Mesoblast will be the third. A lot of research going into Stem Cell therapies, and it is extremely complex.
Interestingly, and what sets ECQ apart, is that they are not researching Mesenchymal stem cells, but their precursor, mesenchymoangioblasts (MCA), which seems quite revolutionary, and more complex than complex, so it will be interesting to see how they progress with this research. It will be slow progress, but if effective, the advantages of deriving infinite cells from only one, rather than having to continually retrieve bone marrow (or other tissues), could be important.
It is good to see that the company is registered in California, because that is where most of the investment capital is for Biotechnology.
I have read the paper on mesenchymoangioblasts (MCA) stem cells a few times, and have shown it to some doctors, who also have to read it a number of times to try and get even a partial understanding.
Cynata has "exclusive" access to investigate MCAs, discovered by company co-founder, Professor Igor Slukvin, and is in the process of negotiating an exclusive global license.
Also looking forward to a change of name, currently sounds like the name for a bunch of tree-hugging green eco-warriors, quite humorous really. Not that I have anything against tree hugging (done a bit of it myself). I expect when the acquisition is complete, the company will be named Cynata Biomed, or something similar.
Gw
ECQ Price at posting:
1.7¢ Sentiment: LT Buy Disclosure: Held